Biogen Eyes Midyear BIIB080 Data, High-Dose SPINRAZA Approvals Boost Outlook
Biogen expects midyear proof-of-concept data for its tau-targeting BIIB080 following positive Phase 1b tau reduction results. The company also gained US, Japanese and European approvals for high-dose SPINRAZA and braces for two Phase 3 LITIFILIMAB SLE trial readouts this year.
1. BIIB080 Proof-of-Concept Midyear
Biogen is developing BIIB080, an antisense oligonucleotide targeting tau to reduce pathological tau accumulation in the brain. The Phase 1b trial demonstrated significant tau reduction and Biogen is exploring various dosing regimens, with midyear proof-of-concept data expected to assess cognitive improvements.
2. High-Dose SPINRAZA Approvals and Uptake
High-dose SPINRAZA has received approval in the US, Japan and Europe, marking a key expansion of the spinal muscular atrophy franchise. Early patient feedback has been positive and initial uptake suggests a strong revenue tailwind from increased dosing levels.
3. LITIFILIMAB Phase 3 SLE Readouts
Biogen has two Phase 3 trials evaluating LITIFILIMAB in systemic lupus erythematosus, with top-line data due later this year. The company is considering a combined filing strategy based on the totality of trial outcomes if one trial is positive and the other shows trending results.
4. LEQEMBI Adoption via Blood-Based Biomarkers
Adoption of LEQEMBI maintenance treatment is being supported by CMS allowing blood-based biomarker confirmation, accelerating patient access. A primary care pilot aims to drive broader use of biomarkers and may encourage physicians to switch patients from Kisunla to LEQEMBI maintenance therapy.